Evaluating the benefit of Gene Expression Profiling (GEP) in early breast cancer

Registration form

Dataset established by the Domain Task Force Convention GEP.

Definition GEP target group:

Patients with early breast cancer, first diagnosis, pN0 or pN1, maximum 5 cm in greatest dimension, HER2-, ER+ and/or PR+, after primary surgery without prior neoadjuvant systemic therapy.

For all patients within this group, 2 registrations need to be performed:

- → The specific GEP registration, irrespective of GEP request
- → The obligatory general cancer registration (Bijlage 55 / Annexe 55)



All variables are required to be filled out unless stated otherwise. O Single-select variables: only one answer can be selected Multi-select variables: one or more answers can be selected
Administrative patient data
Hospital:
Health insurance institution:
National number for social security (INSZ/NISS)*:
* if filled out in the online WBCR application, the following variables will be completed automatically:
Last name:
First name:
Postal code:
Country:
Health insurance number:(if possible) Date of birth:/(dd/mm/yyyy)
Date of birth:/
Sex: O Male
○ Female
1. Information on the tumour
- Detection by:
O Screening
O Symptomatic
O Unknown
- Laterality:
O Unilateral
O Bilateral
- Specify the laterality of the tumour for which the GEP registration is applicable:
O 1. Left
O 2. Right
- Multifocality:
O Unifocal O Multifocal
O Multifocal
Tumour details (related to the tumour/focus on which the decision to administer or not to administer adjuvant chemotherapy is based in case of a bilateral or multifocal tumour):
- Tumour size on resection specimen (greatest dimension): (mm) - ER:
- Percentage of positive tumour cells: (%) or Allred category: (0-8)
- Interpretation:
O +
O -
- PR:
- Percentage of positive tumour cells: (%) or Allred category: (0-8)
- Interpretation:
O +



-	O No	ecimen?			
	O Yes				
	- Highest Ki67 value?	(%)			
_	Procedure used for lymph node analy	, ,			
	☐ Sentinel lymph node biopsy				
	☐ Axillary dissection				
_	Number of lymph nodes retrieved:				
-	Number of positive lymph nodes:				
	- Size of the largest metastatic de	eposit on lymp	oh node:	(mm)	
-	Tumour grade:				
	O Grade 1 (total score 3 - 5)				
	O Grade 2 (total score 6 - 7)				
	O Grade 3 (total score 8 - 9)				
	O Unknown				
	Please indicate the breakdown of	the tumour a	ade.		
		•	O Score 2	O Score 3	O Unknown
	 Tubule and gland formation: 				
	- Mitotic score:		O Score 2		
	Willoud Goorg.	3 00010 1	3 00010 2	3 00010 0	3 Officiowii
2.	At MOC/COM				
-	Date surgery://	. (dd/mm/yyy	y)		
-	Date MOC/COM://				
-	Was a GEP test considered for this pa	atient during t	he MOC/COM	1?	
	O No				
	- Reason:				
	 All clinical/patholog 	ical paramete	rs are fully co	ncordant to in	dicate a (very)
	low risk				
	 All clinical/patholog 	ical paramete	rs are fully co	ncordant to in	dicate a (very)
	high risk				
	O Patient comorbiditie	•			
	O Clinic reached the r	number of reir	nbursements	of GEP for cu	rrent year
	O Other				
	•	ty:			
	O Yes				
	- Reason:				
	O Clinical high riskO Other				
	- What would be the MOC				tha GED2
	O Strong recommend			•	
	Weak recommenda		-		•
	O Strong recommend		•	•	
	Strong recommendaWeak recommenda		· ·		,
	- What does the MOC wan		•		
	Request GEP test	to propose t	o and patient:		
	O No request GEP test	st			



3

3. A	t po	stope	erative	consu	ıltatio	on afte	r MOC	/COM	(befo	ore r	eque	st of	GEP)		
- [ate	of the	postor	perative	con	sultatior	า:	/	/		(d	d/mm	/yyyy	')		
			-			sed with					•			,		
	O	No														
	O	Yes														
- V	Vas	it deci	ded to	reques	t a G	EP?										
	O	No														
		-	Reas	on for n	ot re	questing	g GEP:									
						proposa										
			0			nts chem P and a			how,	desp	oite ac	lvise	of MC	OC/CC	OM to	
			O	Patien	t doe	s not wa	ant che	mothe	rapy,	desp	oite ad	vise o	of MC	C/CC)M to	
				reques	st GE	P and a	wait res	sults								
			O	Other												
				- [Pleas	se speci	fy:									
		-	Final	treatme	ent: V	Vas adju	uvant ch	hemoth	nerap	y init	iated	(at lea	ast 1	cycle	receiv	ed)?
				No												
			O	Yes												
				- \		h regime										
						Anthra	-	-								
						Anthra	-									
						Doceta	axel cyc	lophos	sphan	nide						
					0	Other	- 1	.,								
						- F	Please	specify	/:							
			In case	e no Gl	EP w	as requ	ested, t	the reg	istrat	tion e	nds h	ere!				
	O	Yes														
		-			•	sting GI										
						proposa										
						ysician	proposa	al (not	MOC	C/COI	M)					
				Patien	t requ	uest										
4. O	-		P was	reques	sted:	GEP re	esult (1	final s	ituat	tion)	and a	adjuv	ant d	chem	othera	apy
			P resu	lt avails	ahle.	/		<u> </u>	(1	dd/m	m/\^\	v)				
			rest?	avanc			/		(0		, ууу	<i>3 </i>				
•	_			nt by Ag	endia	а										
	-	-	•):										
	O	Mam				y UZ Le										
		-	•):										



O Other

Test result (value):

Test result (value):

O Mammaprint on NGS, by Institut Jules Bordet

Oncotype DX by Genomic Health

	Interpretation of GEP result (as stated on the report):
	O High risk
	O Intermediate / Borderline risk
	O Low risk
	O Technical failure
	What would be the treatment decision of the treating physician now that the GEP test result is
	available (irrespective of the preference of the patient)?
	 Strong recommendation to administer adjuvant chemotherapy
	Weak recommendation to administer adjuvant chemotherapy
	 Strong recommendation not to administer any chemotherapy
	Weak recommendation not to administer any chemotherapy
	Final treatment: Was adjuvant chemotherapy initiated (at least 1 cycle received)?
	O No
	- Main reason:
	 Patient does not want chemotherapy
	O Proposed by the treating physician or at the MOC/COM:
	- Motivation:
	O Other:
	- Motivation:
	O Yes
	- Main reason:
	O Patient wants chemotherapy
	O Proposed by the treating physician or at the MOC/COM:
	O GEP high risk and clinical high risk
	O Other
	- Motivation:
	O Other:
	- Motivation:
	- Which regimen?
	O Anthracycline only
	O Anthracycline and taxane
	O Docetaxel cyclophosphamide
	O Other
	- Please specify:
•	Did the GEP result influence the confidence of the treating physician in the treatment
	decision?
	No impactMore confident
	O Less confident

